MiCardia Receives Two New U.S. Patents For Its Dynamic Adjustable Cardiac Implant Technology

Main Category: Cardiovascular / Cardiology
Article Date: 07 Apr 2008 - 1:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

MiCardia Corporation announced the United States Patent Office has notified the Company that a new patent has been issued. This key patent, titled, "Adjustable Cardiovascular Implants and Methods for Reshaping Tissue," along with the recently issued patent titled, "Shape Memory Devices and Methods for Reshaping Heart Anatomy," surround the foundation of MiCardia's Dynaplasty Technology.

MiCardia is an emerging company developing the novel Dynaplasty Technology for the percutaneous and non-invasive treatment of structural heart disease including Mitral Valve Regurgitation, Tricuspid Valve Regurgitation and Congestive Heart Failure ("CHF"). Dynaplasty Technology provides devices that can be implanted into the heart and then dynamically adjusted either during the procedure or post-operatively for the proper shape and size to produce the maximal clinical outcome at the time of the surgery or at long-term time periods post-operatively.

MiCardia's Dynaplasty Technology platform will provide intra-operative, percutaneous and completely non-invasive dynamically adjustable devices for the $15 billion CHF market.

The Company continues to expand its intellectual property portfolio and currently has 4 pending and 30 filed patents surrounding late-stage heart failure as well as the ability to expand this platform to other clinical applications (e.g. adjustable aortic heart valves, etc).

Commenting on these new patents, MiCardia Chairman, Michael Henson said, "These patents provide broad intellectual property coverage for MiCardia's fundamental technology. We expect a number of additional patents to be issued over the next year. In addition to building a strong intellectual property foundation, we have completed a number of major milestones during the past six months, including the completion of our long-term GLP animal studies and first-in-man human clinical usage trials. We expect to begin a multi-center European clinical study within the next few months."

MiCardia is a development-stage company located in Irvine, California. MiCardia is developing dynamically activated implantable devices for the treatment of heart disease.

MiCardia